HCA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HCA Healthcare is a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The stock demonstrates strong financial performance, positive analyst sentiment with increasing price targets, and favorable long-term growth prospects driven by AI-driven efficiency gains. Despite some insider selling, the overall outlook remains positive for long-term investment.
The technical indicators show mixed signals. The MACD is negative and expanding downward, suggesting bearish momentum. However, the RSI is neutral, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), indicating an overall upward trend. The stock is trading near its pivot point of 534.645, with resistance at 544.34 and support at 524.95.
Strong financial performance in Q4 2025, with revenue up 6.72% YoY, net income up 30.60% YoY, and EPS up 44.58% YoY.
Positive analyst sentiment with multiple price target increases, including UBS raising the target to $635 and Mizuho to $
AI-driven efficiency gains and industry-leading margins are expected to drive long-term growth.
Insider selling has increased significantly (1487.91% over the last month), which could indicate caution from insiders.
The MACD is negative, suggesting potential short-term bearish momentum.
No recent news or event-driven catalysts to provide additional momentum.
HCA Healthcare reported strong Q4 2025 financials: Revenue increased by 6.72% YoY to $19.51B, net income surged by 30.60% YoY to $1.88B, and EPS grew by 44.58% YoY to $8.14. Gross margin remained stable at 80.07%, reflecting solid operational efficiency.
Analysts are overwhelmingly positive on HCA Healthcare, with multiple price target increases over the past month. UBS raised its target to $635, Mizuho to $585, and Cantor Fitzgerald to $588, citing strong fundamentals, AI-driven efficiency gains, and industry-leading margins. However, some analysts, like Bernstein, remain cautious due to high valuations and potential headwinds to EBITDA growth.
